Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets slip
Thu, 28 Feb 01:30 pm

Not enthused by the Budget proposals, Indian share markets pared gains and slipped below the dotted line in the post-noon trading session. Majority of the sectoral indices are trading negative with banking, capital goods and oil and gas stocks being the biggest losers. Only FMCG, consumer durable, IT and realty stocks are trading in the green.

BSE-Sensex is down 26 points and NSE-Nifty is trading down by 8 points. While BSE Mid Cap is down 0.3%, BSE Small Cap index is trading up by 0.2%. The rupee is trading at 54.0 to the US dollar.

Majority of the domestic pharma stocks are trading in the red with Strides Arcolab and Panacea Biotech being the major losers. However, Dishman Pharma and J B Chemicals are trading strongly. As per a leading financial daily, Cipla has offered to acquire 100% stake in Cipla Medpro South Africa for a consideration of US$ 512 m. The offer will be implemented through a scheme of arrangement and is subject to regulatory and other approvals including approval by Medpro shareholders. The proposed acquisition will be made either directly or through a subsidiary and will largely be funded by internal accruals. The South African market is a fast emerging market with demand for generic drugs projected to grow at around 14% in future. This acquisition is in line with Cipla's strategy to have a sales market outside India.

All the aluminium stocks are trading in the red with Hindalco and National Aluminium Company Ltd. (NALCO) being among the top losers. As per a leading financial daily, Hindalco Industries has announced a lock-out at its aluminium foil manufacturing plant at Silvassa, in the Union Territory of Dadra and Nagar Haveli due to prolonged workers' strike. Set up in 1998, the plant has a capacity of 30,000 tonnes per annum and a rolling capacity of 9 to 100 microns. The products from the plant are supplied to pharmaceutical companies such as GlaxoSmithKline, Pfizer, Lupin, Aventis, Cadila and Torrent. The unit also exports to 11 countries across Europe, West Asia, South Asia, Australia and Far East.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.